Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria.
Cerebral malaria is a significant cause of global mortality, causing an estimated two million deaths per year, mainly in children. The pathogenesis of this disease remains incompletely understood. Chemokines have been implicated in the development of cerebral malaria, and the IFN-inducible CXCR3 chemokine ligand IP-10 (CXCL10) was recently found to be the only serum biomarker that predicted cerebral malaria mortality in Ghanaian children. We show that the CXCR3 chemokine ligands IP-10 and Mig (CXCL9) were highly induced in the brains of mice with murine cerebral malaria caused by Plasmodium berghei ANKA. Mice deficient in CXCR3 were markedly protected against cerebral malaria and had far fewer T cells in the brain compared with wild-type mice. In competitive transfer experiments, CXCR3-deficient CD8(+) T cells were 7-fold less efficient at migrating into the infected brains than wild-type CD8(+) T cells. Adoptive transfer of wild-type CD8(+) effector T cells restored susceptibility of CXCR3-deficient mice to cerebral malaria and also restored brain proinflammatory cytokine and chemokine production and recruitment of T cells, independent of CXCR3. Mice deficient in IP-10 or Mig were both partially protected against cerebral malaria mortality when infected with P. berghei ANKA. Brain immunohistochemistry revealed Mig staining of endothelial cells, whereas IP-10 staining was mainly found in neurons. These data demonstrate that CXCR3 on CD8(+) T cells is required for T cell recruitment into the brain and the development of murine cerebral malaria and suggest that the CXCR3 ligands Mig and IP-10 play distinct, nonredundant roles in the pathogenesis of this disease.
Campanella
Gabriele S V
GS
Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
Tager
Andrew M
AM
El Khoury
Joseph K
JK
Thomas
Seddon Y
SY
Abrazinski
Tabitha A
TA
Manice
Lindsay A
LA
Colvin
Richard A
RA
Luster
Andrew D
AD
D000818:Animals; D001921:Brain / Q000469:parasitology / Q000473:pathology; D017252:CD3 Complex / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology / Q000469:parasitology; D002465:Cell Movement; D054357:Chemokine CXCL10 / Q000235:genetics / Q000276:immunology*; D054370:Chemokine CXCL9 / Q000235:genetics / Q000276:immunology*; D008024:Ligands; D016779:Malaria, Cerebral / Q000276:immunology* / Q000469:parasitology / Q000473:pathology* / Q000517:prevention & control; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010962:Plasmodium berghei / Q000276:immunology; D054367:Receptors, CXCR3 / Q000276:immunology*; D018121:Receptors, Cytokine / Q000172:deficiency; D013154:Spleen / Q000378:metabolism / Q000473:pathology; D015996:Survival Rate; D015854:Up-Regulation / Q000235:genetics
D017252:CD3 Complex; D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; C104577:IP10-Mig receptor; D008024:Ligands; D054367:Receptors, CXCR3; D018121:Receptors, Cytokine